menu
    • menu
    [{"orgOrder":0,"company":"Health Hope Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Health Hope Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Health Hope Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Health Hope Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Health Hope Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Health Hope Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Health Hope Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Health Hope Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Health Hope Pharma","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Health Hope Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Health Hope Pharma \/ PharmaEssentia","highestDevelopmentStatusID":"10","companyTruncated":"Health Hope Pharma \/ PharmaEssentia"},{"orgOrder":0,"company":"Health Hope Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Encequidar","moa":"P-glycoprotein 1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Health Hope Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Health Hope Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Health Hope Pharma \/ Gilead Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Health Hope Pharma

    Menu

    Health Hope Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Health Hope Pharma

                            Hong Kong arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Health Hope Pharma

                            Hong Kong arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encequidar

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences

                            Details : HHP and Hanmi Pharm will grant Gilead exclusive global rights to encequidar, a first-in-class P-glycoprotein inhibitor, within the field of virology.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 29, 2025

                            Lead Product(s) : Encequidar

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Health Hope Pharma

                            Hong Kong arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Health Hope Pharma

                            Hong Kong arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

                            Details : Paclitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 19, 2025

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Health Hope Pharma

                            Hong Kong arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Health Hope Pharma

                            Hong Kong arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eribulin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate Eribulin ORA in Subjects With Solid Tumors

                            Details : Eribulin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 09, 2019

                            Lead Product(s) : Eribulin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Health Hope Pharma

                            Hong Kong arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Health Hope Pharma

                            Hong Kong arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : PharmaEssentia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

                            Details : Paclitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            May 24, 2017

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : PharmaEssentia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.